Literature DB >> 23904826

Immunotherapy in breast cancer - towards a new understanding of both tumor and host.

Peter C Dubsky1, Giuseppe Curigliano.   

Abstract

Entities:  

Year:  2012        PMID: 23904826      PMCID: PMC3515787          DOI: 10.1159/000342629

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  8 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

Authors:  John Stagg; Fabrice Andre; Sherene Loi
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

3.  Profiling the immune stromal interface in breast cancer and its potential for clinical impact.

Authors:  Sheeba Irshad; Anita Grigoriadis; Katherine Lawler; Tony Ng; Andrew Tutt
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

4.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

Review 5.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

6.  Tumor-associated antigens in breast cancer.

Authors:  Carmen Criscitiello
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

  8 in total
  1 in total

Review 1.  Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Authors:  Andrea Ravelli; James M Reuben; Francesco Lanza; Simone Anfossi; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Paola Brambilla; Manuela Milani; Daniele Spada; Paolo Pedrazzoli; Massimo Martino; Alberto Bottini; Daniele Generali
Journal:  Tumour Biol       Date:  2015-08-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.